Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
Blood Cancer J
.
2016 Mar 11;6(3):e403.
doi: 10.1038/bcj.2016.12.
Authors
D C Phillips
,
Y Xiao
,
L T Lam
,
E Litvinovich
,
L Roberts-Rapp
,
A J Souers
,
J D Leverson
PMID:
26967820
PMCID:
PMC4817096
DOI:
10.1038/bcj.2016.12
No abstract available
Publication types
Published Erratum